Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE9)
BERLIN:GE9
Genmab A/S (GE9) Stock Price & Analysis
6 Followers
GE9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€228.00 - €384.40
Previous Close€253
Volume0.00
Average Volume (3M)N/A
Market Cap
€16.49B
Enterprise Value€12.83B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)22.6
Beta0.60
Next Earnings
Aug 01, 2024EPS Estimate
€2.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.20
Shares Outstanding66,122,964
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.09
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.05
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€327.30Price Target Upside29.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Genmab A/S News
Bulls Say, Bears Say
Bulls Say
Approval And Market OpportunityThe FDA granted accelerated approval for Epkinly's label expansion in 3L+ FL, making it the only CD20 x CD3 TCE bispecific approved for both DLBCL and FL in the R/R setting.
Positive Clinical DataGenmab presented impressive overall survival data for GEN1046 in refractory lung patients, with a survival rate of 17.5 months, significantly ahead of cross-trial comparison benchmarks.
Regulatory MilestoneThe recent FDA vote to accept MRD-ve as a surrogate for myeloma first-line drug development is very important for Genmab, potentially accelerating the drug's market entry.
Bears Say
Commercial ExecutionInvestor focus for Epkinly will continue to be on commercial execution and positioning versus competitors.
Pipeline ProgressPipeline progress through FY24 is imperative to build confidence in growth post Darzalex LOE.
Safety ConcernsExpect some investor questions to persist around liver safety and profile of data in a small PII.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
68.86% Mutual Funds
8.67% Other Institutional Investors
22.46% Public Companies and
Individual Investors
GE9 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €228.00 and its highest was €384.40 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Aug 01, 2024 which is in 9 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on May 02, 2024. The company reported €2.702 earnings per share for the quarter, beating the consensus estimate of €1.73 by €0.972.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is €2.86.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,136,910 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €2.702 in its last earnings report, beating expectations of €1.73. Following the earnings report the stock price went up 1.041%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE9
---
Genmab A/S Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€327.30 (29.37% Upside)
€327.30 (29.37% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.95%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
20.68%
Trailing 12-Months
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
GE9 Stock 12 Month Forecast
Average Price Target
€327.30
▲(29.37% Upside)
Technical Analysis
Best Analysts Covering GE9
1 Year
1 Year Success Rate
19/32 ratings generated profit
1 Year Average Return
+17.05%
reiterated a buy rating 5 days ago
Copying Emily Field's trades and holding each position for 1 Year would result in 59.38% of your transactions generating a profit, with an average return of +17.05% per trade.
---